# Safety and Efficacy Study of IPX159 in Restless Legs Syndrome (RLS)

> **NCT01521663** · PHASE2 · COMPLETED · sponsor: **Impax Laboratories, LLC** · enrollment: 159 (actual)

## Conditions studied

- Restless Legs Syndrome

## Interventions

- **DRUG:** IPX159
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01521663
- **Lead sponsor:** Impax Laboratories, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 159 (ACTUAL)
- **Last updated:** 2017-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01521663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01521663, "Safety and Efficacy Study of IPX159 in Restless Legs Syndrome (RLS)". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT01521663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*